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Background:Mostatrialﬁbrillation (AF)epidemiologydescribedWesternpopulations; there is apaucityof
data from Chinese ethnicity. This study presented differences in patient characteristics and management
strategies, and assessed the quality of life (QoL) and AF control in Taiwanese patients from RealiseAF.
Methods: RealiseAF enrolled 10,523 patients internationally, in which Taiwanese cohort accounts for
7.1%. Physicians were randomly selected from a global list. Patient characteristics, management and
therapeutic strategies of AF, QoL measured by the EQ-5D questionnaire, and the control of AF (in sinus
rhythm, or AF with a ventricular rate ≤80 beats per minute) evaluated by electrocardiography were
assessed.
Results: Taiwanese patients were mostly outpatients (93.9%), older (70.2±11.8 years), accompanied
by more comorbidities, more frequently (51.7%) in permanent AF, and symptomatic (European Heart
Rhythm Association score ≥II: 81.5%) compared with the non-Taiwanese cohort. A rhythm-control strat-
egy was less preferable to rate-control than in non-Taiwanese cohort as well as the use of class I and III
antiarrhythmic drugs (AADs); 85.2% of Taiwanese patients received AADs, among which beta-blockers
were the most common (46.9%). QoL was compromised (Visual Analogue Scale: 70.3±14.4; single index
utility score: 0.81±0.25) and only 48.6% of the Taiwanese patients had AF controlled.
Conclusions: AF complexity in the Taiwanese cohort was similar to or even greater than that in the non-
Taiwanese cohort. The Taiwanese patients were highly symptomatic; QoL was impaired despite the
widespread use of medications and AF control was unsatisfactory. There is an apparent unmet need in
AF treatment in Chinese ethnicity.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Abbreviations: AAD, antiarrhythmic drug; AF, atrial ﬁbrillation; EHRA, European
eart RhythmAssociation; EHS-AF, Euroheart survey on atrial ﬁbrillation; EORP-AF,
uroObservational research programme atrial ﬁbrillation; PREFER in AF, prevention
f thromboembolic events – European registry in atrial ﬁbrillation; QoL, quality
f life; RealiseAF, real-life global survey evaluating patients with atrial ﬁbrillation;
ecordAF, registry on cardiac rhythm disorders; RecordAF-AP, registry on cardiac
hythm disorders – Asia Paciﬁc.
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Atrial ﬁbrillation (AF) is associated with increased cardiovas-
cular events and mortality [1,2]. The management of AF involves
rhythm- and/or rate-control strategies in addition to thromboem-
bolism prevention. However, neither of the strategies is superior
with regard to major cardiovascular endpoints or quality of life
(QoL) [3–6]. Studies of antiarrhythmic drugs (AADs) focus on the
effectiveness of restoration and maintenance of sinus rhythm, and
the reduction of cardiovascular events [7,8]. In contrast, symptoms
and QoL considerably impaired by AF are seldom prospectively
served.
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valuated [5,6,9]. There is limited information regarding the impact
f AF on QoL in the Asian population [10,11]. The real-life global
urvey evaluating patients with atrial ﬁbrillation (RealiseAF) is the
argest international survey on the management of all types of
F [12]. RealiseAF showed that AF was accompanied by multiple
ardiovascular risk factors and comorbidities, and control of AF
as unsatisfactory, particularly in patients with a higher burden
f symptoms and compromised QoL [12,13]. Nevertheless, the epi-
emiology and management of AF vary across continents [14,15].
ifferences in both patient and AF characteristics and in the treat-
ent preferences across registries are attributed to the distribution
f patient enrollment [13,16–18]. Since the majority of Taiwanese
atients in RealiseAF were recruited during clinic visits, we exam-
ned the differences in patient characteristics, clinical presentation
f AF, and treatment between the Taiwanese cohort, the third
argest population enrolled in RealiseAF, and the non-Taiwanese
ohort to assess contemporary AF epidemiology in clinics in addi-
ion to QoL burden in patients of Chinese ethnicity.
ethods
RealiseAF is a large-scale, international, contemporary survey
f >10,000 patients with all types of AF enrolled in 26 countries
rom October 2009 to May 2010. The study was conducted with the
pproval of the appropriate boards in each country. The design and
ain results havebeendescribedpreviously elsewhere [12,13]. The
bjective of RealiseAFwas to provide contemporary information on
atient characteristics and comorbidities, types and management
f AF, AF control and its impact on QoL.
esign and overview of RealiseAF
Regardless of the treatment, patients with a history of AF
ocumented by electrocardiography or Holter monitoring in the
revious 12 months or documented current AF, who provided
ritten informed consent were eligible. Physicians were randomly
elected from the global list of cardiologists and internists, in a
atio predetermined to reﬂect the practice in each country. Study
hysicianswere asked to recruit 10–30 consecutive patientswithin
weeks.
The type of AF was judged by the study physicians. Lone AF was
eﬁned as AF patients aged <60 years without a history of either
ypertension, heart failure, coronary artery disease, valvular heart
isease, chronic pulmonary disease, or venous thromboembolism.
F-related symptoms on the day of visit were assessed accord-
ng to the European Heart Rhythm Association (EHRA) AF cardiac
ymptom classiﬁcation [19]. The management strategy as either
hythm-control or rate-control before and at the day of visit was
etermined by the study physicians instead of the use of AADs. QoL
n the visit daywasmeasured by using the EQ-5D instrument. Ade-
uate AF control was determined by resting electrocardiography
n the visit day, and was deﬁned as being either in sinus rhythm or
n AF with a resting ventricular rate ≤80 beats per minute (bpm).
s RealiseAF was an observational study, electrocardiography used
or AF control assessmentwas only performed in 91.8% of the study
opulation on the visit day.
bjectives
The objective of this study was to describe the contemporary
F epidemiology in patients of Chinese ethnicity. In RealiseAF, a
arger proportion of Taiwanese patients were recruited on an out-
atient basis compared with the non-Taiwanese cohort. This study
ompared the differences in characteristics and management of AF
etween two different enrollment patterns.iology 64 (2014) 211–217
Furthermore, in contrast to the global study physicians, of
whom 83.1% were cardiologists, all 34 study physicians from 22
sites in Taiwan who enrolled ≥1 patient were cardiologists (aged
43.5±7.7 years, electrophysiologists: 29.4%), who were also the
actual treating physicians of their enrollees. A majority (85.3%) of
Taiwanesephysicians reported that they see<5newlydiagnosedAF
patients perweek, and 47.1% see ≥10 patients perweekwith either
a history of AF or current AF. We assessed AF control and QoL in
the Taiwanese cohort, which was entirely treated by cardiologists.
Statistical analysis
Descriptive information is presented as mean± standard devi-
ation or as the percentage of the population with non-missing
data. The published summary statistics of the global RealiseAF
population was used for statistical comparisons [12]. For com-
parisons between the Taiwanese and non-Taiwanese patients, the
chi-square test was used. Analyses were performed using the
Statistical Analysis Systems statistical software, version 9.1 (SAS
Institute, Cary, NC).
Results
Demographics, risk factors, comorbidities and concomitant
conditions
Of the 10,523 patients enrolled in the global RealiseAF sur-
vey, 16.2% were from Asia (Azerbaijan, India, Taiwan and Turkey),
including 742 patients (7.1%) from Taiwan. The comparisons of
demographics, cardiovascular risk factors and concomitant con-
ditions of the Taiwanese and non-Taiwanese cohorts are listed
in Table 1. Hypertension was the most common risk factor and
heart failure was the most common comorbidity. The distributions
in cardiovascular risk factors and cardiovascular comorbidities
were signiﬁcantly different between the groups. In general, the
Taiwanese patientswere older andhad a higher burden of both car-
diovascular disease and non-cardiovascular comorbidities in spite
of their higher outpatient recruitment rate (93.9% vs. 68.2%). In
addition, a history of diabetes, cerebrovascular disease, valvular
heart disease and sick sinus syndrome was more frequent in the
Taiwanese cohort, while the non-Taiwanese cohort had a higher
prevalence of dyslipidemia, obesity, heart failure and hypothy-
roidism and was less likely to have pulmonary, hepatic and renal
comorbidities. Symptomatic heart failure was similarly distributed
in both cohorts.
Characteristics of AF and QoL impairment
The distributions of AF classiﬁcation, the duration since a diag-
nosis of AF, symptoms and management strategies were different
between the Taiwanese and non-Taiwanese cohorts (Table 2). Non-
permanent AF and lone AF were less frequent in the Taiwanese
cohort, despite the duration of AF being shorter in Taiwanese
cohort. More than half of the Taiwanese cohort (55.3%) had
symptoms in the past 7 days before the visit, whereas a greater pro-
portion of the non-Taiwanese cohort were symptomatic (61.1%),
with particularly palpitation, dyspnea, fatigue, and lightheaded-
ness/dizziness. On the visit day, patients from the Taiwanese cohort
were more frequently symptomatic (EHRA score ≥II: 81.5%) com-
pared with the non-Taiwanese cohort (EHRA score ≥II: 73.3%).
AFwas associatedwithmodestly impairedQoL in the Taiwanese
patients, measured by EQ-5D Visual Analogue Scale (70.3±14.4)
and the single index utility score (0.81±0.25). The patients had
some level of impairment in all ﬁve dimensions of well-being
(Fig. 1).
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Table 1
Demographic and characteristics of patients.
Global RealiseAF Taiwanese cohort Non-Taiwanese cohort p-Value
(n=10,523) (n=742) (n=9781)
Age 66.6±12.2 70.2±11.8 NA NA
Age ≥60 years 73.9 80.1 73.4 <0.001
Age ≥75 years 28.0 41.4 27.0 <0.001
Men 56.4 59.8 56.1 0.050
CVD risk factor
Hypertension 72.2 72.9 72.1 0.650
Diabetes 21.3 27.0 20.9 <0.001
Dyslipidemia 46.3 36.4 47.1 <0.001
Current smoker 10.2 11.5 10.1 0.235
Obesitya 32.7 9.7 34.4 <0.001
Physical inactivity 61.1 69.5 60.4 <0.001
Family history of premature CVD 23.0 17.0 23.5 <0.001
Concomitant disease
Heart failure 45.8 40.7 46.2 0.004
NYHA-FC ≥IIb 87.9 90.5 87.8 0.197
Coronary artery disease 32.3 34.5 32.1 0.186
Cerebrovascular disease 14.1 21.9 13.5 <0.001
Peripheral arterial disease 4.6 3.2 4.7 0.067
Valvular heart disease 26.7 38.8 25.8 <0.001
Sick sinus syndrome 4.3 6.6 4.1 0.001
Hypothyroidism 5.8 2.1 6.0 <0.001
Hyperthyroidism 4.6 5.3 4.6 0.391
Chronic pulmonary disease 10.9 17.3 10.5 <0.001
Liver disease 4.5 14.0 3.8 <0.001
Chronic advanced renal failure 3.9 9.8 3.5 <0.001
≥1 concomitant disease 77.7 84.6 77.2 <0.001
Outpatient recruitment 69.9 93.9 68.2 <0.001
Data are in percentages unless noted otherwise. CVD, cardiovascular disease; NA, not applicable; NYHA-FC, New York Heart Association Functional Classiﬁcation.
a Body mass index ≥30kg/m2.
b Number in percentage of those who had heart failure.
Table 2
Characteristics of AF.
Global RealiseAF Taiwanese cohort Non-Taiwanese cohort p-Value
(n=10,523) (n=742) (n=9781)
Type of AF
First episode 6.4 3.9 6.6 <0.001
Paroxysmal 24.8 33.3 24.2
Persistent 22.3 11.1 23.2
Permanent 46.4 51.7 46.0
Non-permanent AF 53.6 48.3 54.0 0.003
Lone AFa 5.1 3.4 5.2 0.029
Time since the diagnosis of AF (months) 53.1±70.7 47.9±62.0 NA NA
<3 months 20.6 19.3 20.7 0.011
3–6 months 6.3 8.3 6.1
6–12 months 10.2 12.6 10.0
≥12 months 62.9 59.8 63.1
Symptoms in the past 7 days
Palpitation 33.8 28.2 34.2 <0.001
Dyspnea 39.4 25.1 40.5 <0.001
Fatigue 35.5 16.3 36.9 <0.001
Lightheadedness/dizziness 15.3 19.5 15.0 0.001
Chest pain 15.3 14.2 15.4 0.361
Syncope 1.9 1.9 1.9 0.992
≥1 symptom 60.7 55.3 61.1 0.002
EHRA score on the visit day
I 26.1 18.5 23.9 <0.001
II 51.8 69.5 50.5
III 20.1 11.2 20.8
IV 2.0 0.8 2.0
II–IV 73.9 81.5 73.3 <0.001
Data are in percentages unless noted otherwise. AF, atrial ﬁbrillation; EHRA, European Heart Rhythm Association; NA, not applicable.
a Lone AF was deﬁned as AF patients aged <60 years without either hypertension, heart failure, coronary artery disease, valvular heart disease, chronic pulmonary disease,
or venous thromboembolism.
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reatment
Rate control was the most preferred treatment strategy by the
tudy physicians both before the visit and on the visit day. The
aiwanese cohort was less likely to be reassigned to another treat-
ent strategy. Similarly, the Taiwanese patients were less likely to
eceive cardioversion; particularly none of the Taiwanese patients
eceived electrical cardioversion comparedwith 961patients in the
on-Taiwanese cohort who received the cardioversion within the
ast 12 months before the visit.Medications indicated for AF stratiﬁed according to Vaughan
illiams classiﬁcation are listed in Table 3. The distribution of
ADs on the visit day was consistent with the use before the visit.
verall, 85.2% and 88.3% of the Taiwanese cohort were prescribed
able 3
anagement strategies and distributions of AADs.
Global RealiseAF Taiwan
(n=10,523) (n=74
Management strategy before the visita
Rhythm control 34.6 21.8
Rate control 53.8 65.5
None 11.7 12.7
Management strategy after the visita
Rhythm control 37.3 24.5
Rate control 57.6 67.8
None 5.1 7.7
Strategy changea 15.3 7.5
Cardioversion in the past 12 months
By class I AAD 5.4 1.1
By class III AAD 9.8 3.5
Electrical cardioversion 9.2 0
Medications in the past 7 days
≥1 class Ia AAD 0.4 0.3
≥1 class Ic AAD 6.7 5.0
Propafenone 4.1 4.6
≥1 class III AAD 24.0 17.8
Amiodarone 21.0 17.7
Sotalol 2.6 0.1
≥1 beta-blocker 56.8 43.5
≥1 CCB 16.4 34.0
≥1 cardiac glycoside 29.5 29.9
Medications on the visit day
≥1 class Ia AAD 0.4 0.3
≥1 class Ic AAD 6.5 5.5
Propafenone 4.0 5.3
≥1 class III AAD 25.8 19.3
Amiodarone 22.3 19.1
Sotalol 2.5 0.1
≥1 beta-blocker 50.2 46.9
≥1 CCB 13.8 35.7
≥1 cardiac glycoside 27.3 30.3
ata are in percentages unless noted otherwise. AAD, antiarrhythmic drug; CCB, calcium
a Management strategies were determined by physicians, not the use of AADs.iology 64 (2014) 211–217
≥1 AAD before the visit and on the visit day, respectively. Class
III AADs, speciﬁcally amiodarone, were the most commonly
prescribed medications with a rhythm-control property in the
Taiwanese cohort; amiodarone and sotalol were relatively under-
used comparedwith their use in the non-Taiwanese cohort. Among
medications with a rate-control property, there was a substantial
difference in the distributions of beta-blockers, calcium channel
blockers and cardiac glycosides between the Taiwanese and
non-Taiwanese cohorts. Beta-blockers were more frequently used
in the non-Taiwanese cohort, whereas patients from Taiwan were
prescribed calcium channel blockers more than twice as frequently
as non-Taiwanese cohort.
The therapeutic management based on the recommendations
of 2006 ACC/AHA/ESC guidelines [20] and the stratiﬁcations of AF
characteristics is shown in Fig. 2. Among328patientswithparoxys-
mal or persistent AF, 9.5% and 0.3% were prescribed ≥1 class Ic AAD
and sotalol, respectively; amiodarone was prescribed for 30.5% of
the cohort. Aminority (21.6%) of the prescriptionswerenot compli-
ant with 2006 ACC/AHA/ESC guidelines. Patients with permanent
AFweremore frequentlyprescribedbeta-blockers anddigoxin. Cal-
cium channel blockers and class III AADs were more commonly
used in patients with a ﬁrst AF episode. However, 2.1% and 8.4% of
patients with permanent AF were prescribed class I and III AADs,
respectively.Control of AF in Taiwanese cohort on the visit day
Among 284 patients who had an electrocardiogram on the visit
day eligible for AF control assessment, 18.7% were in sinus rhythm
ese cohort Non-Taiwanese cohort p-Value
2) (n=9781)
35.5 <0.001
52.9
11.6
38.2 <0.001
56.7
4.9
15.8 <0.001
5.7 <0.001
10.2 <0.001
9.9 <0.001
0.5 0.453
6.8 0.059
4.0 0.461
24.5 <0.001
21.2 0.022
2.8 <0.001
57.8 <0.001
15.1 <0.001
29.5 0.817
0.4 0.638
6.6 0.247
3.9 0.081
26.3 <0.001
22.5 0.034
2.7 <0.001
50.4 0.065
12.2 <0.001
27.1 0.059
-channel blocker.
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tig. 2. The use of class Ic and III AADs on the visit day in paroxysmal or persistent
ermanent AF (C) and ﬁrst episode of AF (D). Appropriate conditions refer to 2006 A
nd 81.3% still in AF. Only 48.6% of the Taiwanese patients had
F adequately controlled (Fig. 3). The control rate was increased
o 87.0% by a more lenient deﬁnition (sinus rhythm or AF with a
entricular rate <110bpm).
iscussion
The main ﬁnding of our analyses indicates the substantial dif-
erences in AF epidemiology with regard to patient characteristics,
linical presentation of AF, and treatment between the Taiwanese
nd non-Taiwanese cohorts in RealiseAF. Furthermore, the burden
f compromised QoL was great in the Taiwanese patients and the
ontrol of AF was unsatisfactory.
ig. 3. The distribution of atrial ﬁbrillation control on the visit day. (Adequate con-
rol is deﬁned by the RealiseAF protocol as being either in sinus rhythm or in atrial
brillation with a resting ventricular rate ≤80 beats per minute.) AF, atrial ﬁbrilla-
ion; HR, heart rate.and the condition of prescriptions (B). The distribution of AADs on the visit day in
HA/ESC guidelines [20]. AAD, antiarrhythmic drug; AF, atrial ﬁbrillation.
Comorbidity
The majority of the large-scale epidemiological information on
AF comes from North America and Europe, and the sources of data
gathered largely contribute to the diversity of the epidemiology
[16,21]. Contemporary studies often include speciﬁc types rather
than full spectrum of AF [14,15]. In addition, Asian patients repre-
sented only 10% of the entire registry on cardiac rhythm disorders
(RecordAF), and Chinese ethnicity accounted for 36% of the entire
registry on cardiac rhythm disorders – Asia Paciﬁc (RecordAF-AP).
There is a paucity of data from patients of Chinese ethnicity, par-
ticularly in patients with permanent AF. RealiseAF is the largest
up-to-date survey on all types of AF. The prevalence of cardiovas-
cular risk factors and comorbidities was higher in the Taiwanese
patients, although 93.9% of the Taiwanese cohort were outpatients.
This more likely reﬂects the status seen in routine clinical practice
than the global RealiseAF and the Euro heart survey on atrial ﬁbril-
lation (EHS-AF) (outpatients: 69.9% and 34%, respectively) [12,16].
In RecordAF-AP, which enrolled 2629 non-permanent AF patients
from eight Asia Paciﬁc countries, the burden of cardiovascular risk
factors and comorbidities, including symptomatic heart failure,
was comparably modest in contrast to that in our population [15].
In addition, previous reports suggest a lower prevalence of coro-
nary artery disease in Japanese patients [10,11,17]. However, our
ﬁnding was consistent with other studies indicating that coronary
artery disease generally presents in one-third of the AF patients
[12,16,21].
Symptoms and QoLBefore the visit, the Taiwanese patients were less symptomatic
than the non-Taiwanese patients (55.3% vs. 61.1). The difference in
recruitment strategy was probably attributed to this phenomenon.
A similar observation was identiﬁed in EuroObservational research
2 f Card
p
t
t
s
p
a
i
m
t
r
o
u
L
u
t
s
[
M
t
T
r
7
t
T
A
p
t
f
[
t
h
a
l
o
2
R
n
p
a
t
i
b
[
A
[
A
s
s
n
t
n
8
h
(
(
g
w
A
o16 K.-L. Wang et al. / Journal o
rogramme atrial ﬁbrillation (EORP-AF), inwhich 65.4%were inpa-
ients and 60.6% were currently symptomatic [22]. On the visit day,
he Taiwanese cohort was highly symptomatic (81.5% had an EHRA
core ≥II) compared with the non-Taiwanese cohort (73.3%) and
atients in EHS-AF (73% of persistent AF, 55% of permanent AF) [16]
nd RecordAF (85% in rhythm control, 76% in rate control) [23]. The
nformation contradicts data from RecordAF-AP reporting that the
ajority of Asian patients were asymptomatic (71%), particularly
hose who had more sustained AF (76%) or who were assigned to a
ate-control strategy (74%) [15]. Beyond symptoms, the assessment
f the impact of AF onQoL in Asian patientswas limited to the eval-
ation of speciﬁc drugs or invasive treatment strategies [10,11,24].
ikewise, QoL was comparably impaired in spite of the widespread
se of AADs by the Taiwanese patients, which is consistent with
he previous reports showing that increased age and burden of
ymptoms, and comorbidities are associated with worsening QoL
25,26].
anagement strategy
As permanent AF was more common in Taiwanese patients,
he rate-control strategy was more frequently adopted in the
aiwanese cohort as well as in 64% of RecordAF-AP population
egardless of symptoms [15]. The change in strategy occurred in
.5% of the Taiwanese patients with rhythm control and rate con-
rol equally distributed. Less preference of rhythm control in the
aiwanese cohort also reﬂects on the underuse of class I and III
ADs. Rhythm control was preferred in cohorts in which non-
ermanent AF accounted for a larger proportion [13,14,16]. From
he global perspective, beta-blockers were overwhelmingly pre-
erred to calcium-channel blockers regardless of AF characteristics
13,14,16]. However, therewas amodest difference in theuse of the
wo therapies in the Taiwanese cohort, particularly in those who
ad the ﬁrst episode AF. Our ﬁnding was in line with the previous
nalysis targeting RecordAF investigators that beta-blockers were
ess prescribed byAsian physicians comparedwith physicians from
ther regions [18].
Divergence between AF management in clinical practice and
006 ACC/AHA/ESC guidelines was observed in EHS-AF and
ecordAF [16,18]. Amiodarone was more frequently prescribed in
on-permanentAF than class Ic AADs and sotalol [13]. In Taiwanese
atients with paroxysmal or persistent AF, 21.6% received man-
gement inconsistent with 2006 ACC/AHA/ESC guidelines, mainly
he prescription of amiodarone, which was similar to the ﬁndings
n the global RealiseAF population and prevention of thromboem-
olic events – European registry in atrial ﬁbrillation (PREFER in AF)
27,28]. Thesedisparitiesmaybe largely related to thepreferenceof
sian physicians in using amiodarone instead of treatment failure
18].
F control
AF control in the Taiwanese cohort was considerably less
atisfactory than that in the global RealiseAF population. A recent
tudy indicated that lenient rate control (a target of <110bpm) was
oninferior to strict rate control (a target of <80bpm) with regard
o major clinical outcomes, symptom burden and QoL in perma-
ent AF patients [29,30]. Although the control rate increased to
7.0% based on a more lenient target, the Taiwanese patients were
ighly symptomatic (81.5%) compared with either lenient control
45.7%), failed strict control (34.9%), or successful strict control
51.3%) in that clinical trial [30], and in the rate-control strategy
roup RecordAF (76%) and Record-AP (26%) [14,15]. Our ﬁndings
ere in accordance with the result of PREFER in AF, indicating that
F-related symptoms reﬂect a suffering from AF per se instead
f the adequacy of rate control in some patients [28]. Furtheriology 64 (2014) 211–217
follow-ups are needed to discuss whether there is an ethnicity dif-
ference in the association of AF control and AF-related symptoms.
Study physician
All study physicians from Taiwan were cardiologists and
29.4% specialized in electrophysiology. There were possibili-
ties that cardiologists, particularly electrophysiologists, had more
symptomatic and complicated patients. The unique data in the Tai-
wanese cohort may be attributable to such a condition in addition
to the ethnicity differences. Similarly, EORP-AF and PREFER in AF
enrolled patients of all types of AF predominantly by cardiologists
indicated the consistent distributions of comorbidities and symp-
tomatic burdens [22,28]. However, rhythm-control strategy was
more preferred by European physicians, and class I AAD and sotalol
were more frequently adopted compared with the preference of
Taiwanese physicians.
Limitations
First, we did not analyze the individual source data from
the global RealiseAF population but used tabulated information
instead. Second, all study physicians from Taiwan were hospital-
based practicing cardiologists. The results may point toward an
overexpression of hospitals specialized in AF treatment and may
not reﬂect the general condition in Taiwan. However, our main
ﬁndingswere consistentwith the reports fromglobal RealiseAF and
EHS-AF, both of which enrolled patients from a variety of sources.
In addition, the complexity of AF illustrated in the RealiseAF Tai-
wanese cohort was in accordance with the observation of the
younger community cohort [2]. Third, the EQ-5D questionnaire
used to assess QoL is validated but not disease-speciﬁc compared
with other questionnaires, which are not available in Mandarin
[31]. In addition, the adequacy of AF control depended solely on
resting electrocardiography on the visit day. We did not assess
the heart rate during exercise. A single snapsot might not repre-
sent the overall adequacy of control. Furthermore, only 38.3% of
the Taiwanese cohort had electrocardiography and the mean heart
rate was 86±21bpm. The actual AF control rate might be overes-
timated. Finally, RealiseAF was a cross-sectional design. Additional
follow-up studies will be needed to answer whether the features
observed in the Taiwanese cohort will contribute to outcomes.
We are currently conducting a 3-year follow-up in the Taiwanese
cohort.
Conclusion
AF represents a signiﬁcant global healthcare burden, whereas
the majority of Taiwanese patients recruited as stable outpatients
had multiple risk factors and comorbidities, similar to those in
other regions, regardless of the enrollment patterns. AF control
was unsatisfactory in Taiwan, particularly the greater burden of
symptoms and compromised QoL despite the widespread use of
medications. Thishighlights anunmetneed indiseasemanagement
to minimize functional impairment in Chinese AF patients.
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